USBC insider grant and repricing create 15M-option exposure at $1.10
Rhea-AI Filing Summary
USBC insider option activity: The company's Chief Operating Officer participated in targeted option adjustments and a new grant. Outstanding options covering 7,140,000 shares were repriced from $2.45 to $1.10 and remain subject to the original vesting schedule that vests 25% after one year with quarterly vesting thereafter. In addition, a new option for 7,860,000 shares was granted at an exercise price of $1.10 with the same vesting pattern, producing a total of 15,000,000 underlying shares held after the transactions. The repriced and newly granted options have exercise windows stretching to 2035 and carry standard multi-year vesting to align with future service.
Positive
- Exercise price reduced from $2.45 to $1.10 on 7,140,000 option shares to restore incentive value
- New grant of 7,860,000 options at $1.10 aligns long-term pay with future performance
- Standard vesting (25% after one year, then quarterly) promotes retention over multi-year period
Negative
- Total potential dilution of 15,000,000 shares underlying options held by the reporting person
- Large option volume may increase shareholder dilution risk and prompt governance scrutiny
- Repricing reduces strike which benefits option holders even if company share price has not improved
Insights
Repricing plus a large new grant materially changes incentive geometry for the executive.
The repricing lowered the strike from $2.45 to $1.10 on 7,140,000 option shares and a separate 7,860,000 share option was newly granted at $1.10. Both sets vest 25% after one year with quarterly vesting thereafter and have terms into 2035. This reduces immediate exercise cost and increases potential upside sensitivity to the share price.
Dependencies include future stock performance and retention via vesting; the cost to holders rises if the market price remains below the new strike. Monitor granted-vs-outstanding option totals and any disclosure of expected dilution in upcoming reporting over the next 12–36 months.
Board-approved repricing and large option awards raise dilution and governance questions.
The Board approved repricing on 10/07/2025 and issued a new long-term option, resulting in 15,000,000 option shares outstanding for this reporting person. Such size is material relative to many issuers and creates clear potential dilution to shareholders if exercised.
Key risks include shareholder perception of executive compensation practices and the need for clear disclosure of the rationale; watch for proxy disclosures or shareholder communications in the next annual meeting cycle and any retained equity-availability metrics over the following year.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Option to Purchase Common Stock | 7,140,000 | $0.00 | -- |
| Grant/Award | Option to Purchase Common Stock | 7,140,000 | $0.00 | -- |
| Grant/Award | Option to Purchase Common Stock | 7,860,000 | $0.00 | -- |
Footnotes (1)
- The transactions reported involved the repricing of outstanding stock options to purchase 7,140,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), initially granted on August 6, 2025 (the "Grant Date"). The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years. On October 7, 2025, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors the Company approved a repricing of outstanding stock options granted on August 6, 2025. The exercise price of each repriced option was reduced from $2.45 to $1.10 per share. On October 7, 2025, the Reporting Person was granted an option to purchase 7,860,000 shares of the Issuer's common stock pursuant to the Amended and Restated 2021 Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.
